Teladoc and Pfizer Shares Drop Over 50%, but Have Bright Long-Term Outlooks
-
Teladoc and Pfizer stocks have dropped 50%+ recently but have great long-term potential.
-
Teladoc is recovering by balancing growth and profitability, focusing on whole person care and chronic conditions.
-
Pfizer's revenue declines are mostly due to lower COVID product demand, but new products and deals will drive future growth.
-
Both Teladoc and Pfizer have attractive valuations now, with Teladoc near record lows and Pfizer trading below peers.
-
The upcoming bull market could significantly boost these stocks as their businesses progress.